These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605 [TBL] [Abstract][Full Text] [Related]
3. Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization. Santin AD; Bellone S; Van Stedum S; Bushen W; De Las Casas LE; Korourian S; Tian E; Roman JJ; Burnett A; Pecorelli S Gynecol Oncol; 2005 Jul; 98(1):24-30. PubMed ID: 15894362 [TBL] [Abstract][Full Text] [Related]
4. HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma. Afify AM; Werness BA; Mark HF Exp Mol Pathol; 1999 Jun; 66(2):163-9. PubMed ID: 10409445 [TBL] [Abstract][Full Text] [Related]
5. [Clinical significance of Her-2/neu status in patients with uterine papillary serous carcinoma]. Ren YL; Wang HY; Zhou XY; Shan BE; Yang WT; Shen L; Shi DR Zhonghua Fu Chan Ke Za Zhi; 2010 May; 45(5):367-71. PubMed ID: 20646447 [TBL] [Abstract][Full Text] [Related]
6. Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization. Liu HL; Gandour-Edwards R; Lara PN; de Vere White R; LaSalle JM Cancer J; 2001; 7(5):395-403. PubMed ID: 11693898 [TBL] [Abstract][Full Text] [Related]
7. Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival. Saffari B; Jones LA; el-Naggar A; Felix JC; George J; Press MF Cancer Res; 1995 Dec; 55(23):5693-8. PubMed ID: 7585656 [TBL] [Abstract][Full Text] [Related]
8. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma. Khan AJ; King BL; Smith BD; Smith GL; DiGiovanna MP; Carter D; Haffty BG Clin Cancer Res; 2002 Feb; 8(2):540-8. PubMed ID: 11839675 [TBL] [Abstract][Full Text] [Related]
9. Identification of HER-2/neu oncogene amplification by fluorescence in situ hybridization in stage I endometrial carcinoma. Riben MW; Malfetano JH; Nazeer T; Muraca PJ; Ambros RA; Ross JS Mod Pathol; 1997 Aug; 10(8):823-31. PubMed ID: 9267826 [TBL] [Abstract][Full Text] [Related]
10. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms. Wu Y; Soslow RA; Marshall DS; Leitao M; Chen B Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965 [TBL] [Abstract][Full Text] [Related]
11. Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression. Bhargava R; Naeem R; Marconi S; Luszcz J; Garb J; Gasparini R; Otis CN Hum Pathol; 2001 Dec; 32(12):1344-50. PubMed ID: 11774167 [TBL] [Abstract][Full Text] [Related]
12. HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization. Odicino FE; Bignotti E; Rossi E; Pasinetti B; Tassi RA; Donzelli C; Falchetti M; Fontana P; Grigolato PG; Pecorelli S Int J Gynecol Cancer; 2008; 18(1):14-21. PubMed ID: 17451461 [TBL] [Abstract][Full Text] [Related]
13. Potential for HER-2/neu molecular targeted therapy for invasive bladder carcinoma: comparative study of immunohistochemistry and fluorescent in situ hybridization. Matsubara H; Yamada Y; Naruse K; Nakamura K; Aoki S; Taki T; Tobiume M; Zennami K; Katsuda R; Honda N Oncol Rep; 2008 Jan; 19(1):57-63. PubMed ID: 18097576 [TBL] [Abstract][Full Text] [Related]
14. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer. Prati R; Apple SK; He J; Gornbein JA; Chang HR Breast J; 2005; 11(6):433-9. PubMed ID: 16297088 [TBL] [Abstract][Full Text] [Related]
15. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization. Persons DL; Borelli KA; Hsu PH Mod Pathol; 1997 Jul; 10(7):720-7. PubMed ID: 9237184 [TBL] [Abstract][Full Text] [Related]
16. Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing. Schmidt M; Lewark B; Kohlschmidt N; Glawatz C; Steiner E; Tanner B; Pilch H; Weikel W; Kölbl H; Lehr HA Breast Cancer Res; 2005; 7(2):R256-66. PubMed ID: 15743506 [TBL] [Abstract][Full Text] [Related]
17. Clinical significance of Her-2/neu overexpression in uterine serous carcinoma. Díaz-Montes TP; Ji H; Smith Sehdev AE; Zahurak ML; Kurman RJ; Armstrong DK; Bristow RE Gynecol Oncol; 2006 Jan; 100(1):139-44. PubMed ID: 16182348 [TBL] [Abstract][Full Text] [Related]
18. HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder. Coogan CL; Estrada CR; Kapur S; Bloom KJ Urology; 2004 Apr; 63(4):786-90. PubMed ID: 15072912 [TBL] [Abstract][Full Text] [Related]
19. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy]. Wülfing C; von Struensee D; Bierer S; Bögemann M; Hertle L; Eltze E Aktuelle Urol; 2005 Sep; 36(5):423-9. PubMed ID: 16163605 [TBL] [Abstract][Full Text] [Related]
20. Her-2/neu expression and gene amplification in gastrinomas: correlations with tumor biology, growth, and aggressiveness. Goebel SU; Iwamoto M; Raffeld M; Gibril F; Hou W; Serrano J; Jensen RT Cancer Res; 2002 Jul; 62(13):3702-10. PubMed ID: 12097278 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]